Media coverage about Marinus Pharmaceuticals (NASDAQ:MRNS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.0093595097671 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern’s analysis:
A number of research firms have weighed in on MRNS. ValuEngine upgraded shares of Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. JMP Securities reiterated an “outperform” rating and set a $11.00 price target (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) traded up 13.23% during mid-day trading on Friday, reaching $5.99. The company’s stock had a trading volume of 1,705,231 shares. The firm’s market cap is $156.19 million. Marinus Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $8.22. The company has a 50-day moving average of $5.13 and a 200-day moving average of $2.58.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. On average, analysts predict that Marinus Pharmaceuticals will post ($0.74) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Marinus Pharmaceuticals (NASDAQ:MRNS) Receiving Somewhat Positive Press Coverage, Accern Reports” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/28/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-marinus-pharmaceuticals-mrns-stock-price.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.